541 related articles for article (PubMed ID: 17764544)
1. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
2. High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling.
Bastien R; Lewis TB; Hawkes JE; Quackenbush JF; Robbins TC; Palazzo J; Perou CM; Bernard PS
Hum Mutat; 2008 May; 29(5):757-64. PubMed ID: 18348286
[TBL] [Abstract][Full Text] [Related]
3. Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.
Vorkas PA; Christopoulos K; Kroupis C; Lianidou ES
Clin Biochem; 2010 Jan; 43(1-2):178-85. PubMed ID: 19747471
[TBL] [Abstract][Full Text] [Related]
4. Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments.
Tindall EA; Petersen DC; Woodbridge P; Schipany K; Hayes VM
Hum Mutat; 2009 Jun; 30(6):876-83. PubMed ID: 19280649
[TBL] [Abstract][Full Text] [Related]
5. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis.
Tessitore A; Di Rocco ZC; Cannita K; Ricevuto E; Toniato E; Tosi M; Ficorella C; Frati L; Gulino A; Marchetti P; Martinotti S
Genes Chromosomes Cancer; 2002 Sep; 35(1):86-91. PubMed ID: 12203794
[TBL] [Abstract][Full Text] [Related]
6. DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples.
Song C; Castellanos-Rizaldos E; Bejar R; Ebert BL; Makrigiorgos GM
Clin Chem; 2015 Nov; 61(11):1354-62. PubMed ID: 26432802
[TBL] [Abstract][Full Text] [Related]
7. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue.
Fadhil W; Ibrahem S; Seth R; Ilyas M
J Clin Pathol; 2010 Feb; 63(2):134-40. PubMed ID: 20154035
[TBL] [Abstract][Full Text] [Related]
8. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y; Bodmer WF
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):976-81. PubMed ID: 16418264
[TBL] [Abstract][Full Text] [Related]
9. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
10. COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations.
Milbury CA; Li J; Makrigiorgos GM
Clin Chem; 2009 Dec; 55(12):2130-43. PubMed ID: 19815609
[TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic strategy for analytical scanning of BRCA1 gene by fluorescence-assisted mismatch analysis using large, bifluorescently labeled amplicons.
Ricevuto E; Sobol H; Stoppa-Lyonnet D; Gulino A; Marchetti P; Ficorella C; Martinotti S; Meo T; Tosi M
Clin Cancer Res; 2001 Jun; 7(6):1638-46. PubMed ID: 11410501
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
15. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
16. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation.
Schneider BG; John-Aryankalayil M; Rowsey JJ; Dushku N; Reid TW
Exp Eye Res; 2006 Jan; 82(1):91-8. PubMed ID: 16005868
[TBL] [Abstract][Full Text] [Related]
18. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
19. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
20. A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model.
Chou LS; Lyon E; Wittwer CT
Am J Clin Pathol; 2005 Sep; 124(3):330-8. PubMed ID: 16191501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
